BACKGROUND The Health Product Profile Directory (HPPD) is an online database describing 8-10 key characteristics (such as target population, measures of efficacy and dosage) of product profiles for medicines, vaccines, diagnostics and other products that are intended to be accessed by populations in low- and middle-income countries. The HPPD was developed by TDR on behalf of WHO and launched on 15 May 2019. METHODS The contents of the HPPD were downloaded into an Excel™ spreadsheet via the open access interface and analysed to identify the number of health product profiles by type, disease, year of publication, status, author organization and safety information. RESULTS The HPPD contains summaries of 215 health product profiles published between 2008 and May 2019, 117 (54%) of which provide a hyperlink to the detailed publication from which the summary was extracted, and the remaining 98 provide an email contact for further information. A total of 55 target disease or health conditions are covered, with 210 profiles describing a product with an infectious disease as the target. Only 5 product profiles in the HPPD describe a product for a non-communicable disease. Four diseases account for 40% of product profiles in the HPPD; these are tuberculosis (33 profiles, 15%), malaria (31 profiles, 14%), HIV (13 profiles, 6%) and Chagas (10 profiles, 5%). CONCLUSION The HPPD provides a new tool to inform priority-setting in global health - it includes all product profiles authored by WHO (n = 51). There is a need to standardise nomenclature to more clearly distinguish between strategic publications (describing research and development (R&D) priorities or preferred characteristics) compared to target product profiles to guide a specific candidate product undergoing R&D. It is recommended that all profiles published in the HPPD define more clearly what affordability means in the context where the product is intended to be used and all profiles should include a statement of safety. Combining the analysis from HPPD to a mapping of funds available for R&D and those products in the R&D pipeline would create a better overview of global health priorities and how they are supported. Such analysis and increased transparency should take us a step closer to measuring and improving coordination of efforts in global health R&D.

中文翻译：

---

卫生产品资料目录分析-一种新的工具，可为全球公共卫生中的优先事项提供信息。

背景技术“健康产品档案目录”（HPPD）是一个在线数据库，描述了8-10个关键特征（例如目标人群，功效和剂量指标），用于药品，疫苗，诊断剂和其他拟由其访问的产品的产品档案低收入和中等收入国家的人口。HPPD由TDR代表世卫组织开发，并于2019年5月15日启动。方法HPPD的内容通过开放访问界面下载到Excel™电子表格中，并进行分析以识别按类型，疾病，出版年份，状态，作者组织和安全信息。结果HPPD包含2008年至2019年5月之间发布的215种保健产品简介的摘要，其中有117个（54％）提供了指向要从中提取摘要的详细出版物的超链接，其余98个提供了电子邮件联系人以获取更多信息。总共涵盖了55种目标疾病或健康状况，其中210种描述了以传染病为目标的产品。HPPD中只有5种产品档案描述了一种非传染性疾病的产品。在HPPD中，四种疾病占产品概况的40％。它们是结核病（33个特征，占15％），疟疾（31个特征，占14％），艾滋病毒（13个特征，占6％）和恰加斯（10个特征，占5％）。结论HPPD提供了一种新的工具，可为全球卫生领域的优先事项提供信息-它包括WHO撰写的所有产品资料（n = 51）。与目标产品简介相比，有必要对术语进行标准化，以更清楚地区分战略出版物（描述研发（R＆D）优先事项或首选特性），以指导进行R＆D的特定候选产品。建议在HPPD中发布的所有配置文件更明确地定义在打算使用该产品的情况下，可负担性意味着什么，并且所有配置文件都应包含安全声明。将HPPD的分析与可用于研发的资金以及研发渠道中的那些产品的映射相结合，可以更好地概述全球卫生优先事项及其支持方式。这种分析和增加的透明度应该使我们更进一步地衡量和改善全球卫生研发工作的协调性。